Oral relugolix for the treatment of advanced prostate cancer.

Chow R; Hird A; Lock M

doi:10.1093/oncolo/oyag004

← 뒤로

Oral relugolix for the treatment of advanced prostate cancer.

The oncologist 2026 Vol.31(3)

Chow R, Hird A, Lock M

PMC 전문 ↗ 원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Chow R, Hird A, Lock M (2026). Oral relugolix for the treatment of advanced prostate cancer.. The oncologist, 31(3). https://doi.org/10.1093/oncolo/oyag004

MLA Chow R, et al.. "Oral relugolix for the treatment of advanced prostate cancer.." The oncologist, vol. 31, no. 3, 2026.

PMID 41604311

DOI 10.1093/oncolo/oyag004

같은 제1저자의 인용 많은 논문 (1)

Pivotal studies of pharmacotherapies approved by the US FDA for cancer treatment: a meta-analysis.
The oncologist 2026